Core Viewpoint - The stock of药捷安康-B (02617) has experienced a significant decline, dropping over 10% and currently trading at 84.7 HKD, with a trading volume of 117 million HKD. This decline follows the announcement of a share placement at a discount to the market price [1]. Group 1: Share Placement Details - The company announced a placement of 21 million new shares at a price of 92.85 HKD per share, representing a discount of 17.98% compared to the closing price of 113.2 HKD on January 13 [1]. - The net proceeds from the placement are expected to be 190 million HKD [1]. Group 2: Use of Proceeds - Approximately 60% of the proceeds will be allocated to fund clinical trials for the core product Tinengotinib, which is currently undergoing single-agent treatment for cholangiocarcinoma (CCA) in China, as well as research for other indications of the core product [1]. - About 30% of the funds will be used for the development of other products, including TT-00973, TT-01488, and other molecules [1]. - The remaining 10% will be utilized for working capital and general corporate purposes [1].
药捷安康-B再跌超10% 拟配股净筹1.9亿港元 主要用于核心产品研发